<DOC>
	<DOC>NCT02946931</DOC>
	<brief_summary>To evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition</brief_summary>
	<brief_title>PMS for Idarucizumab in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<criteria>Inclusion criteria: Patients who are prescribed with Prizbind® for Intravenous Solution 2.5 g by the discretion of investigators Exclusion criteria:</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>